Tiphaine Delaunay1, Carole Achard1, Nicolas Boisgerault1, Marion Grard1, Tacien Petithomme1, Camille Chatelain1, Soizic Dutoit1, Christophe Blanquart1, Pierre-Joseph Royer2, Stéphane Minvielle3, Lisa Quetel4, Clément Meiller4, Didier Jean4, Delphine Fradin1, Jaafar Bennouna5, Antoine Magnan6, Laurent Cellerin7, Frédéric Tangy8, Marc Grégoire1, Jean-François Fonteneau9. 1. CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France; Labex IGO, Immunology Graft Oncology, Nantes, France. 2. INSERM, UMRS1087, Institut du Thorax, Université de Nantes, Nantes, France. 3. CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. 4. Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, Université de Paris, Functional Genomics of Solid Tumors, Paris, France. 5. CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France; Labex IGO, Immunology Graft Oncology, Nantes, France; CHU de Nantes, oncologie thoracique et digestive, Université de Nantes, Nantes, France. 6. INSERM, UMRS1087, Institut du Thorax, Université de Nantes, Nantes, France; CHU de Nantes, Service de Pneumologie, Université de Nantes, Nantes, France. 7. CHU de Nantes, Service de Pneumologie, Université de Nantes, Nantes, France. 8. CNRS 3569, Institut Pasteur, Paris, France. 9. CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France; Labex IGO, Immunology Graft Oncology, Nantes, France. Electronic address: jean-francois.fonteneau@inserm.fr.
Abstract
INTRODUCTION: Oncolytic immunotherapy is based on the use of nonpathogenic replicative oncolytic viruses that infect and kill tumor cells exclusively. Recently, we found that the spontaneous oncolytic activity of the Schwarz strain of measles virus (MV) against human malignant pleural mesothelioma (MPM) depends on defects in the antiviral type I interferon (IFN-I) response in tumor cells. METHODS: In this study, we studied three independent human MPM bio-collections to identify the defects in the IFN-I responses in tumor cells. RESULTS: We show that the most frequent defect is the homozygous deletions (HDs) of all the 14 IFN-I genes (IFN-α and IFN-β) that we found in more than half of MV-sensitive MPM cell lines. These HDs occur together with the HDs of the tumor suppressor gene CDKN2A also located in the 9p21.3 chromosome region. Therefore, the IFN-I-/- MPM cell lines develop a partial and weak IFN-I response when they are exposed to the virus compared with that of normal cells and MV-resistant MPM cell lines. This response consists of the expression of a restricted number of IFN-stimulated genes that do not depend on the presence of IFN-I. In addition, the IFN-I-/- MPM cell lines infected by MV also develop a pro-inflammatory response associated with stress of the endoplasmic reticulum. CONCLUSION: Our study emphasizes the link between HDs of IFN-I encoding genes and the CDKN2A gene in MPM and sensitivity to MV oncolytic immunotherapy.
INTRODUCTION: Oncolytic immunotherapy is based on the use of nonpathogenic replicative oncolytic viruses that infect and kill tumor cells exclusively. Recently, we found that the spontaneous oncolytic activity of the Schwarz strain of measles virus (MV) against human malignant pleural mesothelioma (MPM) depends on defects in the antiviral type I interferon (IFN-I) response in tumor cells. METHODS: In this study, we studied three independent human MPM bio-collections to identify the defects in the IFN-I responses in tumor cells. RESULTS: We show that the most frequent defect is the homozygous deletions (HDs) of all the 14 IFN-I genes (IFN-α and IFN-β) that we found in more than half of MV-sensitive MPM cell lines. These HDs occur together with the HDs of the tumor suppressor gene CDKN2A also located in the 9p21.3 chromosome region. Therefore, the IFN-I-/- MPM cell lines develop a partial and weak IFN-I response when they are exposed to the virus compared with that of normal cells and MV-resistant MPM cell lines. This response consists of the expression of a restricted number of IFN-stimulated genes that do not depend on the presence of IFN-I. In addition, the IFN-I-/- MPM cell lines infected by MV also develop a pro-inflammatory response associated with stress of the endoplasmic reticulum. CONCLUSION: Our study emphasizes the link between HDs of IFN-I encoding genes and the CDKN2A gene in MPM and sensitivity to MV oncolytic immunotherapy.
Authors: Antonia Marazioti; Anthi C Krontira; Sabine J Behrend; Georgia A Giotopoulou; Giannoula Ntaliarda; Anne-Sophie Lamort; Georgios T Stathopoulos; Christophe Blanquart; Hasan Bayram; Marianthi Iliopoulou; Malamati Vreka; Lilith Trassl; Mario A A Pepe; Caroline M Hackl; Laura V Klotz; Stefanie A I Weiss; Ina Koch; Michael Lindner; Rudolph A Hatz; Juergen Behr; Darcy E Wagner; Helen Papadaki; Sophia G Antimisiaris; Didier Jean; Sophie Deshayes; Marc Grégoire; Özgecan Kayalar; Deniz Mortazavi; Şükrü Dilege; Serhan Tanju; Suat Erus; Ömer Yavuz; Pınar Bulutay; Pınar Fırat; Ioannis Psallidas; Magda Spella; Ioanna Giopanou; Ioannis Lilis Journal: EMBO Mol Med Date: 2021-12-13 Impact factor: 12.137
Authors: Anca Nastase; Amit Mandal; Shir Kiong Lu; Hima Anbunathan; Deborah Morris-Rosendahl; Yu Zhi Zhang; Xiao-Ming Sun; Spyridon Gennatas; Robert C Rintoul; Matthew Edwards; Alex Bowman; Tatyana Chernova; Tim Benepal; Eric Lim; Anthony Newman Taylor; Andrew G Nicholson; Sanjay Popat; Anne E Willis; Marion MacFarlane; Mark Lathrop; Anne M Bowcock; Miriam F Moffatt; William O C M Cookson Journal: Sci Rep Date: 2021-09-27 Impact factor: 4.379